Toronto-based BenchSci has partnered with Thermo Fisher Scientific to apply artificial intelligence in drug development. The collaboration will allow clients to design experiments using Thermo Fisher’s equipment, analyze results with BenchSci’s software, and recycle the data to guide further discoveries.
CEO Liran Belenzon declined to disclose financial terms but called the deal a step into the “physical world of science.” Founded in 2015, BenchSci’s platform aggregates data from academic research, patents, clinical trials, and pharmaceutical experiments. The company is also developing AI agents capable of generating hypotheses and test designs. Thermo Fisher is a global leader in lab equipment.
Want to know more? Check out the source code on The Logic.